Computer aided biology pioneer Synthace secures $25.6 million in series B funding

Taylor Wessing has advised Synthace Ltd on its $25.6 million series B financing round.

Synthace is a leader in computer aided biology, and the company behind the leading cloud software platform for automating and improving the success rate of biological research and development.

Computer aided biology comprises two domains: the digital and the physcial. The digital, powered by artificial intelligence and the physical, enabled by automation.

Howard Palmer, corporate technology partner, commented:

"Continued investment and commitment to developing new technology which advances industries are values that Synthace shares with us. Companies in this sector face many challenges in order to be competitive, and we're pleased that our expertise and understanding of their needs has contributed to their success."

Tim Fell, CEO of Synthace Ltd added:

"Digital-to-physical workflows have transformed the semiconductor, aerospace, automobile and many other industries. Now it is the turn of the biotechnology industry, and we are grateful for the support of Horizons Ventures and our other new investment partners who share Synthace’s vision of how to facilitate that change. Our thanks go to our team at Taylor Wessing for all the help they have provided us this year. Their support has played a huge part in helping us grow and reach this latest milestone."

Bob Wiederhold, Synthace Chairman, concluded:

“The realisation is setting in across industry and academia that the complexity of biology can only be properly addressed with advanced software and automation. This investment in Synthace is a significant step in turning that recognition into reality.”

The team was led by corporate technology partner Howard Palmer with support from Siobhan Langwade.